Related Experiment Videos
Care of Patients Receiving Abemaciclib: Results From Clinical Trials and a Healthcare Provider Survey
Pamela K Ginex1, Kelli Thoele2, Qinli Ma3
1Pamela K. Ginex.
Background:
Being familiar with the care of patients with breast cancer who are receiving abemaciclib, including adverse event (AE) management, supports care.
Objectives:
This article describes the care of patients with breast cancer receiving abemaciclib, including AE data from clinical trials and nonpharmacologic interventions in real-world practice through a survey of healthcare providers.
Methods:
Safety data from the monarchE, MONARCH 1, MONARCH 2, and MONARCH 3 trials were reviewed. A quantitative survey of advanced practitioners, oncologists, and pharmacists was also conducted to better understand nonpharmacologic interventions to manage patient-felt AEs and support patients receiving abemaciclib.
Findings:
The most common AEs across all MONARCH trials were diarrhea, fatigue, nausea, and neutropenia; most events were grade 1-2. Of 282 survey respondents, more than 90% recommended nonpharmacologic interventions to manage AEs.
Related Concept Videos
Clinical Trials: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Clinical Trials
There are four phases in a clinical trial. A phase one...
Treatment Resistent Cancers
Cancer Survival Analysis
Treatment Resistant Cancers